Citations

Clear

904 citation(s) found for "Gordon, S".

PD-L1 expression in non-clear cell renal cell carcinoma.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Carvo, Ingrid, Lampron, Megan E., Stanton, Melissa, Freeman, Gordon J. , Hirsch, Michelle S. , Callea, Marcella , Ho, Thai H. , McDermott, David F. , Atkins, Michael B. , Signoretti, Sabina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 4_suppl | Pages: 424-424

10.1200/jco.2014.32.4_suppl.424 Get It

424 Background: Programmed death-1 (PD-1) receptor negatively regulates T cell-mediated responses.PD-1 ligand (PD-L1) is aberrantly expressed in clear cell renal cell carcinoma (ccRCC) and is associated with worse prognosis. Levels of PD-L1 expressions in non-ccRCC and its association with clinicopathological features and survival are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 97 patients with chromophobe (CHR), papillary (PAP), translocation Xp11.2 (TrL) RCC and oncoytoma (ONC) and were included in the analysis. PD-L1 expression was evaluated by immunohistochemistry using a mouse monoclonal anti-PD-L1 antibody (405.9A11). The assay was validated using FFPE cell line controls known to be positive or negative for PD-L1 expression by flow cytometry. PD-L1 tumor positivity (PD-L1+) was defined as ≥5% tumor cell membrane staining. For PD-L1 expression in immune cells, a combined score based on the intensity of infiltrate and percentage of positive cells was used. Baseline characteristics including stage/grade, and survival data were collected. Comparisons between PD-L1 expression and clinicopathological features were evaluated using chisq or wilcoxon rank sum tests. Cox model tests for association of PD-L1 expression with OS in univariate and multivariable analysis. Results: Among 97 patients, 12 (12.4%) were considered PD-L1+ in tumor cells: 2/36 (5%) of CHR RCC, 5/50 (10%) of PAP RCC, 3/7 (43%) of TrL RCC, and 2/4 (50%) of ONC. PD-L1 positivity in tumor cells was significantly associated with higher stage (p=0.026) and grade (p=0.046), as well as lower OS on univariate (p=0.02) but not multivariate analysis (p=0.29). On the other hand, PD-L1 positivity by immune cells was observed in 50 (51.5%) patients: 13/36 (36%) of CHR RCC, 30/50 (60%) of PAP RCC, 6/7 (86%) of TrL RCC, and 1/4 (25%) of ONC. PD-L1 positivity in immune cells did not correlate with stage (p=0.7), grade (p=0.1) or OS (p=0.8). Conclusions: PD-L1 expression is variable in non-ccRCC and depends on histology and tumor vs. immune cells scoring. Only PD-L1 positivity in tumors cells was associated with aggressive features. Patients with non-ccRCC should not be automatically excluded from trials of agents that target the PD-1/PD-L1 pathway.
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma
White, Christine A., Wiseman, Gregory A., Emmanouilides, Christos, Raubitschek, Andrew, Janakiraman, Nalini, Gutheil, John, Schilder, Russell J., Spies, Stewart, Parker, Elizabeth U. , Grillo-López, Antonio J, Witzig, Thomas E. , Gordon, Leo I. , Silverman, Daniel H.S.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 17 | Issue: 12 | Pages: 3793-3803

10.1200/jco.1999.17.12.3793 | PMID 10577851 Get It

PURPOSE: Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalently binds MX-DTPA (tiuxetan), which chelates the radioisotope yttrium-90. The antibody targets CD20, a B-lymphocyte antigen. A multicenter phase I/II trial was conducted to compare two doses of unlabeled rituximab given before radiolabeled antibody, to determine the maximum-tolerated single dose of IDEC-Y2B8 that could be administered without stem-cell support, and to evaluate safety and efficacy.PATIENTS AND METHODS: Eligible patients had relapsed or refractory (two prior regimens or anthracycline if low-grade disease) CD20+B-cell low-grade, intermediate-grade, or mantle-cell non-Hodgkin's lymphoma (NHL). There was no limit on bulky disease, and 59% had at least one mass ≥ 5 cm.RESULTS: The maximum-tolerated dose was 0.4 mCi/kg IDEC-Y2B8 (0.3 mCi/kg for patients with baseline platelet counts 100 to 149,000/μL). The overall response rate for the intent-to-treat population (n = 51) was 67% (26% complete response [CR]; 41% partial response [PR]); for low-grade disease (n = 34), 82% (26% CR; 56% PR); for intermediate-grade disease (n = 14), 43%; and for mantle-cell disease (n = 3), 0%. Responses occurred in patients with bulky disease (≥ 7 cm; 41%) and splenomegaly (50%). Kaplan-Meier estimate of time to disease progression in responders and duration of response is 12.9+ months and 11.7+ months, respectively. Adverse events were primarily hematologic and correlated with baseline extent of marrow involvement with NHL and baseline platelet count. One patient (2%) developed an anti-antibody response (human antichimeric antibody/human antimouse antibody).CONCLUSION: These phase I/II data demonstrate that IDEC-Y2B8 radioimmunotherapy is a safe and effective alternative for outpatient therapy of patients with relapsed or refractory NHL. A phase III study is ongoing.
INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy
Minsky, Bruce D. , Pajak, Thomas F., Ginsberg, Robert J., Pisansky, Thomas M. , Martenson, James A., Komaki, Ritsuko , Okawara, Gordon, Kelsen, David P., Rosenthal, Seth A.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 5 | Pages: 1167-1174

10.1200/jco.2002.20.5.1167 | PMID 11870157 Get It

PURPOSE: To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer. PATIENTS AND METHODS: A total of 236 patients with clinical stage T1 to T4, N0/1, M0 squamous cell carcinoma or adenocarcinoma selected for a nonsurgical approach, after stratification by weight loss, primary tumor size, and histology, were randomized to receive combined-modality therapy consisting of four monthly cycles of fluorouracil (5-FU) (1,000 mg/m 2 /24 hours for 4 days) and cisplatin (75 mg/m 2 bolus day 1) with concurrent 64.8 Gy versus the same chemotherapy schedule but with concurrent 50.4 Gy. The trial was stopped after an interim analysis. The median follow-up was 16.4 months for all patients and 29.5 months for patients still alive. RESULTS: For the 218 eligible patients, there was no significant difference in median survival (13.0 v 18.1 months), 2-year survival (31% v 40%), or local/regional failure and local/regional persistence of disease (56% v 52%) between the high-dose and standard-dose arms. Although 11 treatment-related deaths occurred in the high-dose arm compared with two in the standard-dose arm, seven of the 11 deaths occurred in patients who had received 50.4 Gy or less. CONCLUSION: The higher radiation dose did not increase survival or local/regional control. Although there was a higher treatment-related mortality rate in the patients assigned to the high-dose radiation arm, it did not seem to be related to the higher radiation dose. The standard radiation dose for patients treated with concurrent 5-FU and cisplatin chemotherapy is 50.4 Gy.
Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL
Schilder, Russell J., Emmanouilides, C., Vo, Katie D. , Darif, Mohamed, Witzig, Thomas E. , Flinn, Ian W. , Gordon, Leo I. , Molina, Aurelia Alañón

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6562-6562

10.1200/jco.2005.23.16_suppl.6562 Get It

A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99–04)
Okawara, Gordon, Winter, K., Donohue, J H, Pisters, Peter W. T., Crane, Christopher H. , Greskovich, J.F., Anné, P.R., Willet, Christopher G., Bradley, Jeffrey D. , Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 4019-4019

10.1200/jco.2005.23.16_suppl.4019 Get It

Differences in Clinical Activity and Medicare Payments for Female vs Male Ophthalmologists
Reddy, Ashvini K. , Bounds, Gregory , Bakri, Sophie J. , Smith, Justine R. , Haller, Julia A. , Thorne, Jennifer E. , Gordon, Lynn K. , Berrocal, Audina M. , Smith, Justine

Mayo Clinic

JAMA Ophthalmology | January 23, 2017 | Volume: 135 | Issue: 3 | Pages: 205

10.1001/jamaophthalmol.2016.5399 | PMID 28114631 Get It

Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States
Garrett, Giorgia L., Boscardin, John, Lloyd, Amanda Abramson, Ahmed, Rehana L. , Anthony, Tiffany, Bibee, Kristin , Breithaupt, Andrew, Cannon, Jennifer, Chen, Amy , Cheng, J , Fuxench, Zelma C. Chiesa , Colegio, Oscar R. , Curiel‐Lewandrowski, Clara , Guzzo, Christina A. Del, Disse, Max, Dowd, Margaret , Eilers, Robert, Ortiz, Arisa , Golden, Spring, Graves, Michael S., Griffin, John R., Hopkins, R. Samuel, Huang, Conway C. , Jambusaria, Anokhi, Jennings, Thomas , Khetarpal, Shilpi , Kim, Chang-Hyun , Klintmalm, Göran B. , Konicke, Kathryn, Koyfman, Shlomo A. , Lam, Charlene , Leitenberger, Justin J. , Loh, Tiffany Y. , Lowenstein, Stefan E. , Madankumar, Reshmi, Moreau, Jacqueline F. , Nijhawan, Rajiv I. , Ochoa, Shari A. , Olasz, Edit , Otchere, Elaine , Otley, Clark C. , Oulton, Jeremy, Patel, Parth H., Prabhu, Arpan V. , Pugliano‐Mauro, Melissa , Schmults, Chrysalyne D. , Schram, Sarah E., Shih, Allen F. , Shin, Thuzar M. , Soon, Seaver L. , Stein, Jennifer , Sternhell‐Blackwell, Kara, Taylor, Stan, Vidimos, Allison T. , Wu, Peggy A. , Zajdel, Nicholas, Zelac, Daniel E. , Arron, Sarah T. , Kim, Changhyun, Ochoa, Shari, Otley, Clark, Blanc, Paul David , Boscardin, W. John , Morris, Caroline Rose , Bae, Gordon Hyeonjin , Jambusaria‐Pahlajani, Anokhi , Jiang, Shang I. Brian , Karia, Pritesh S. , Lee, Peter, Patel, Vishal Anil , Soriano, Teresa T. , Srivastava, Divya , Nj, Zajdel

Mayo Clinic

JAMA Dermatology | January 17, 2017 | Volume: 153 | Issue: 3 | Pages: 296

10.1001/jamadermatol.2016.4920 | PMID 28097368 Get It

European Society for Medical Oncology Copenhagen update: potential practice-changing findings
Mallarkey, Gordon , Grothey, Axel

Mayo Clinic

Therapeutic Advances in Medical Oncology | January 7, 2017 | Volume: 9 | Issue: 1 | Pages: 4-12

10.1177/1758834016679105 | PMID 28203293 Get It

High‐resolution electrical mapping of porcine gastric slow‐wave propagation from the mucosal surface
Angeli, Timothy R. , Du, Peng , Sathar, Shameer , Asirvatham, S, Farrugia, Gianrico , Windsor, John A. , Cheng, Leo K. , O’Grady, Gregory , Asirvatham, Samuel J. , Paskaranandavadivel, Niranchan , Hall, Andrew , Asirvatham, Samuel J , Angeli-Gordon, Timothy R

Mayo Clinic

Neurogastroenterology & Motility | December 30, 2016 | Volume: 29 | Issue: 5 | Pages: No page available

10.1111/nmo.13010 | PMID 28035728 Get It

AbstractBackgroundGastric motility is coordinated by bioelectrical slow waves, and gastric dysrhythmias are reported in motility disorders. High‐resolution (HR) mapping has advanced the accurate assessment of gastric dysrhythmias, offering promise as a diagnostic technique. However, HR mapping has been restricted to invasive surgical serosal access. This study investigates the feasibility of HR mapping from the gastric mucosal surface.MethodsExperiments were conducted in vivo in 14 weaner pigs. Reference serosal recordings were performed with flexible‐printed‐circuit (FPC) arrays (128‐192 electrodes). Mucosal recordings were performed by two methods: (i) FPC array aligned directly opposite the serosal array, and (ii) cardiac mapping catheter modified for gastric mucosal recordings. Slow‐wave propagation and morphology characteristics were quantified and compared between simultaneous serosal and mucosal recordings.Key ResultsSlow‐wave activity was consistently recorded from the mucosal surface from both electrode arrays. Mucosally recorded slow‐wave propagation was consistent with reference serosal activation pattern, frequency (P≥.3), and velocity (P≥.4). However, mucosally recorded slow‐wave morphology exhibited reduced amplitude (65‐72% reduced, P<.001) and wider downstroke width (18‐31% wider, P≤.02), compared to serosal data. Dysrhythmias were successfully mapped and classified from the mucosal surface, accorded with serosal data, and were consistent with known dysrhythmic mechanisms in the porcine model.Conclusions & InferencesHigh‐resolution gastric electrical mapping was achieved from the mucosal surface, and demonstrated consistent propagation characteristics with serosal data. However, mucosal signal morphology was attenuated, demonstrating necessity for optimized electrode designs and analytical algorithms. This study demonstrates feasibility of endoscopic HR mapping, providing a foundation for advancement of minimally invasive spatiotemporal gastric mapping as a clinical and scientific tool.
Potential Radiation-Related Effects on Radiologists
Parikh, Jay R. , Geise, Richard A., Bluth, Edward I. , Bender, Claire E., Sze, Gordon , Jones, A. Kyle

Mayo Clinic

American Journal of Roentgenology | December 22, 2016 | Volume: 208 | Issue: 3 | Pages: 595-602

10.2214/ajr.16.17212 | PMID 28004978 Get It